The annual international 3Rs award, sponsored by the NC3Rs and GlaxoSmithKline, recognises primary research which has made a significant contribution to advancing the 3Rs in medical, biological or veterinary sciences.
New research revealed by the Cell and Gene Therapy (CGT) Catapult today, indicates that the UK cell and gene therapy industry continues to expand, as the UK establishes itself as a global leader in the development of living medicines.
In its 2017 Annual Review published today, the Cell and Gene Therapy Catapult (CGT Catapult) shares an overview of its work over the past year as it increases its contribution to the UK’s thriving cell and gene therapy sector.
Locate Therapeutics' IntraStem Intracellular Delivery System offers the possibility of increasing MSC transfection rates by up to 200%
Combined with the TAOS Matrix, IntraStem can deliver antibodies, magnetic nanoparticles (MNPs) and nucleic acids (plasmid (p)DNA, mRNA and siRNA) into cells at much higher levels than the current alternatives for reprogramming, as well as improving gene editing, using for example, the CRISPR-cas9 approach
Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, is pleased to announce the appointment of Dr Cliff Holloway as Chief Executive Officer of Scancell, starting 10 January 2018. Cliff will seek to drive progress of Scancell’s immunotherapy platforms ImmunoBody® and Moditope® and oversee their commercialisation. Cliff succeeds Richard Goodfellow who will remain on the Company’s Board of Directors.